Agents for Amyloidosis-Associated Polyneuropathy - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
Customize your policy alerts
Sign up for Oscar Health Policy CG109 alerts
Get alerted when Policy CG109 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-benefit exception requests for physician-administered agents used to treat amyloidosis-associated polyneuropathy. It identifies preferred and non-preferred products and establishes when an exception to the preferred self-administered product may be approved.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.